The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a greater substantial reduction in body size and improve metabolic markers, par